SEC Form 4 · accession 0001521111-26-000005
Nuvation Bio Inc. · NUVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gary Hattersley
Officer — CHIEF SCIENTIFIC OFFICER
Period of report
Aug 19, 2026
Accepted (ET)
Aug 21, 2026 · 4:49 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001811063
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Aug 19, 2026 | M | 100,000 | $1.87 | A | 100,000 | D | |
| Class A Common StockF2 | Aug 19, 2026 | S | 100,000 | $7.0924 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $1.87 | Aug 19, 2026 | M | 100,000 | D | — | Feb 27, 2034 | Class A Common Stock | 100,000 | 400,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
- F2Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.02 to $7.21. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F3Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.